Patents by Inventor Kenneth C. McNulty

Kenneth C. McNulty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20180162845
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 14, 2018
    Inventors: James A. BRACKLEY, III, Alan Peterson GRAVES, III, Steven David KNIGHT, Kenneth C. MCNULTY, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Inhibitors of AKT Activity
    Publication number: 20160287561
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 6, 2016
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160122342
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Inventors: David T. FOSBENNER, Bryan W. KING, Steven David KNIGHT, Louis Vincent LaFRANCE, III, Mei LI, Kenneth C. McNULTY, Stuart Paul ROMERIL, Mark Andrew SEEFELD
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20150152092
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: December 8, 2014
    Publication date: June 4, 2015
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Inhibitors of AkT activity
    Patent number: 8946278
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McNulty
  • INHIBITORS OF Akt ACTIVITY
    Publication number: 20100267759
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 7, 2008
    Publication date: October 21, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Patent number: 7442792
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: October 28, 2008
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James P. Sherbine, Shawn K. Pack, Jaan A. Pesti, Robert E. Yule, Kenneth C. McNulty
  • Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Patent number: 7208596
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: April 24, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James P. Sherbine, Shawn K. Pack, Jaan A. Pesti, Robert E. Yule, Kenneth C. McNulty
  • Process for the hydrocyanation of monoolefins using bidentate phosphite ligands and zero-valent nickel
    Patent number: 5847191
    Abstract: The present invention provides a process for hydrocyanation comprising reacting a nonconjugated, ethylenically unsaturated compound in a two phase process solvent with HCN in the presence of a Lewis acid promoter and a catalyst system comprising zero-valent nickel and an organic phosphorous containing ligand having the structure (PR.sub.2).sub.n R' where n is an integer from 1 to 2, R and R' are organic residues which may be the same or different and where the R or R' contain at least one C9 to C40 aliphatic group positioned as a tail extending away from the primary ligand structure rendering the ligand lipophilic.
    Type: Grant
    Filed: July 29, 1997
    Date of Patent: December 8, 1998
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Emilio Enrique Bunel, Kenneth C. McNulty